Physician profile
Jeffrey Reyes
NPI 1811016710
$4,841.69
in general payments reported to CMS, 2019-2025
22 companies · $1,325 in 2025
The $1,325 reported for 2025 was more than what 87% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $569 · 2022: $422 · 2023: $1,461 · 2024: $1,064 · 2025: $1,325.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,850.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,850.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $893.53 | 2021-2025 | Wainua |
| Boehringer Ingelheim Pharmaceuticals, INC. | $622.31 | 2023-2025 | Jardiance |
| Grifols USA, LLC | $379.66 | 2025 | Hyperrab, Gamunex-C |
| Abbott Laboratories | $273.57 | 2023-2024 | Freestyle Libre 3, Freestyle Libre |
| Scpharmaceuticals INC. | $246.91 | 2025 | |
| Janssen Pharmaceuticals, INC | $229.07 | 2021-2023 | Xarelto |
| Inari Medical, INC. | $167.54 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Novo Nordisk INC | $166.31 | 2021-2022 | |
| Sequel Med Tech, LLC | $157.26 | 2025 | Twiist |
| Averitas Pharma INC. | $154.05 | 2024 | Qutenza |
| Abbvie INC. | $150.00 | 2024 | |
| Mirum Pharmaceuticals, INC. | $144.79 | 2025 | Livmarli |
| Baxter Healthcare | $136.53 | 2022 | |
| Incyte Corporation | $126.82 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $125.00 | 2024 | Arcalyst |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $125.00 | 2023 | Austedo Xr |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $125.00 | 2024 | |
| Merck Sharp & Dohme LLC | $125.00 | 2023 | Recarbrio |
| Sanofi-Aventis U.S. LLC | $123.98 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $123.66 | 2023 | Camzyos |
| Axsome Therapeutics, INC. | $123.19 | 2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $122.51 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Reyes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.